Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer - PubMed (original) (raw)
. 2002 May 1;99(1):130-7.
doi: 10.1002/ijc.10242.
Affiliations
- PMID: 11948504
- DOI: 10.1002/ijc.10242
Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer
Hisae Iinuma et al. Int J Cancer. 2002.
Abstract
Peritoneal dissemination in gastric cancer is a common fatal clinical condition with few effective therapies available. We studied the therapeutic effect of a tumor-targeting drug delivery system that uses cisplatin-encapsulated and Tf-conjugated PEG liposomes (Tf-PEG liposomes) in nude mice with peritoneal dissemination of human gastric cancer cells. Small unilamellar Tf-PEG, PEG or DSPC/CH liposomes (bare liposomes) encapsulating cisplatin were prepared by reverse-phase evaporation followed by extrusion. Electron microscopic studies revealed that Tf-PEG liposomes were internalized into tumor cells by receptor-mediated endocytosis. To examine the biodistribution of each liposome and cisplatin level, nude mice were inoculated i.p. with 10(7) MKN45P human gastric tumor cells. On the fourth day after tumor inoculation, (3)H-CHE-labeled and cisplatin-encapsulated Tf-PEG, PEG or bare liposome were inoculated i.p. The Tf-PEG liposome-administered group maintained high liposome and cisplatin levels in ascites and showed a prolonged residence time in the peripheral circulation. Uptake of Tf-PEG liposomes into the liver and spleen was significantly lower than that of bare liposomes. Uptake of Tf-PEG liposomes in disseminated tumor cells of ascites and the greater omentum was significantly higher than that of PEG or bare liposomes and a significant increase in cisplatin levels was observed in these tumor cells. Mice receiving Tf-PEG liposomes 1 and 4 days after the day of tumor inoculation showed significantly higher survival rates compared with those receiving PEG liposomes without Tf, bare liposomes or free cisplatin solution. These results suggest that cisplatin-encapsulated Tf-PEG liposomes may be useful as a new intracellular targeting carrier for treatment of gastric cancer with peritoneal dissemination.
Copyright 2002 Wiley-Liss, Inc.
Similar articles
- Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo.
Ishida O, Maruyama K, Tanahashi H, Iwatsuru M, Sasaki K, Eriguchi M, Yanagie H. Ishida O, et al. Pharm Res. 2001 Jul;18(7):1042-8. doi: 10.1023/a:1010960900254. Pharm Res. 2001. PMID: 11496943 - [Transferrin conjugated PEG-liposomes as intracellular targeting carrier for tumor therapy].
Ishida O, Maruyama K. Ishida O, et al. Nihon Rinsho. 1998 Mar;56(3):657-62. Nihon Rinsho. 1998. PMID: 9549352 Review. Japanese. - Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT).
Maruyama K, Ishida O, Kasaoka S, Takizawa T, Utoguchi N, Shinohara A, Chiba M, Kobayashi H, Eriguchi M, Yanagie H. Maruyama K, et al. J Control Release. 2004 Aug 11;98(2):195-207. doi: 10.1016/j.jconrel.2004.04.018. J Control Release. 2004. PMID: 15262412 - Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome.
Suzuki R, Takizawa T, Kuwata Y, Mutoh M, Ishiguro N, Utoguchi N, Shinohara A, Eriguchi M, Yanagie H, Maruyama K. Suzuki R, et al. Int J Pharm. 2008 Jan 4;346(1-2):143-50. doi: 10.1016/j.ijpharm.2007.06.010. Epub 2007 Jun 16. Int J Pharm. 2008. PMID: 17640835 - PEG-immunoliposome.
Maruyama K. Maruyama K. Biosci Rep. 2002 Apr;22(2):251-66. doi: 10.1023/a:1020138622686. Biosci Rep. 2002. PMID: 12428903 Review.
Cited by
- Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy.
Zhong J, Wen W, Wang J, Zhang M, Jia Y, Ma X, Su YX, Wang Y, Lan X. Zhong J, et al. Pharm Res. 2023 Jan;40(1):231-243. doi: 10.1007/s11095-022-03430-8. Epub 2022 Nov 15. Pharm Res. 2023. PMID: 36380167 Free PMC article. - Nanoparticle-Based Drug Delivery System: A Patient-Friendly Chemotherapy for Oncology.
Yan L, Shen J, Wang J, Yang X, Dong S, Lu S. Yan L, et al. Dose Response. 2020 Jul 10;18(3):1559325820936161. doi: 10.1177/1559325820936161. eCollection 2020 Jul-Sep. Dose Response. 2020. PMID: 32699536 Free PMC article. - Tuning hydrated nanoceria surfaces: experimental/theoretical investigations of ion exchange and implications in organic and inorganic interactions.
Vincent A, Inerbaev TM, Babu S, Karakoti AS, Self WT, Masunov AE, Seal S. Vincent A, et al. Langmuir. 2010 May 18;26(10):7188-98. doi: 10.1021/la904285g. Langmuir. 2010. PMID: 20131920 Free PMC article. - Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects.
Song Z, Lin Y, Zhang X, Feng C, Lu Y, Gao Y, Dong C. Song Z, et al. Int J Nanomedicine. 2017 Mar 10;12:1941-1958. doi: 10.2147/IJN.S125573. eCollection 2017. Int J Nanomedicine. 2017. PMID: 28331317 Free PMC article. - Virosomes of hepatitis B virus envelope L proteins containing doxorubicin: synergistic enhancement of human liver-specific antitumor growth activity by radiotherapy.
Liu Q, Jung J, Somiya M, Iijima M, Yoshimoto N, Niimi T, Maturana AD, Shin SH, Jeong SY, Choi EK, Kuroda S. Liu Q, et al. Int J Nanomedicine. 2015 Jun 25;10:4159-72. doi: 10.2147/IJN.S84295. eCollection 2015. Int J Nanomedicine. 2015. PMID: 26203243 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous